Search Results

offset rate, using rapid calcium assays Potency Is a Ratio of Rates Two ligands compete for the same receptor monophasic curves, you’ll see biphasic signatures or sequential shifts—first cholinesterase inhibition, then receptor

trust us in the generation of their monoclonal antibodies against small molecules and transmembrane receptors

novel GPR52 agonist HTL00411718 to modulate centrally mediated locomotor activity in response to A2A receptor

TRV045 is the Company’s novel S1P1 receptor modulator being developed as a potential treatment for diabetic

results in the production of bioactive C3a, a product of C3 cleavage, which interacts with membrane-bound receptor

Dipraglurant selectively targets the metabotropic glutamate receptor subtype 5 (mGlu5) through allosteric

drug discovery and development, announced today that it has moved a selective and potent M4 muscarinic receptor

The talks given targeted both traditional GPCRs such as the serotoninergic receptor 5HT1A, but also newer

pain-relieving compounds that, like morphine and other drugs, provide relief via activation of opioid receptors

Quantitative systems pharmacology (QSP) modeling is an emerging mechanistic computational approach that couples

The vision is to develop novel muscarinic receptor agonists for schizophrenia and other neuropsychiatric

Evaluation of the observed shifts relative to thermodynamic estimates for the coupling between binding

Taking advantage of a striking deficit of both NPS receptor (NPSR1) and NPS precursor knockout mice in

authorization for the Company’s TAVNEOS (avacopan), an orally administered selective complement 5a receptor

ADX71149 is a selective metabotropic glutamate type 2 (mGlu2) receptor positive allosteric modulator

Must-read publications:  AT1R β-arrestin bias; UII receptor structure; β2AR constant-pH dynamics. Your Membership Gives You: Proven frameworks used in real discovery programs On-demand lessons built

Physiological relevance:  Fluorescent ligands can retain receptor integrity—critical when signaling readouts

What happens when receptor expression is different? What happens in vivo? Are Models Ever Proven? Here’s the uncomfortable truth: you can never prove a model “right.”